Conversion of Bim-BH3 from Activator to Inhibitor of Bak through Structure-Based Design
Jason M Brouwer, Ping Lan, Angus D Cowan, Jonathan P Bernardini, Richard W Birkinshaw, Mark F van Delft, Brad E Sleebs, Adeline Y Robin, Ahmad Wardak, Iris K Tan, Boris Reljic, Erinna F Lee, W Douglas Fairlie, Melissa J Call, Brian J Smith, Grant Dewson, Guillaume Lessene, Peter M Colman, Peter E Czabotar
Molecular Cell | CELL PRESS | Published : 2017
Awarded by NHMRC
Awarded by NHMRC (Australia)
Awarded by Leukemia and Lymphoma Society (U.S.) (SCOR)
We thank Janet Newman and colleagues at the CSIRO C3 crystallization facility; Matthew Call for discussions; Jai Rautela, Mike Ryan, David Huang, David Segal, Sweta Iyer, and Michael Dengler for reagents and technical assistance; and Natasha Ritchie for proofreading the manuscript. This research was undertaken in part using the MX1 and MX2 crystallography beamlines at the Australian Synchrotron, Victoria, Australia, and made use of the ACRF Detector. P.E.C., G.L., and P.M.C. acknowledge NHMRC Fellowships (1079700, 1117089, 1116934). Our work is supported by NHMRC (Australia; Projects Grants 1079706 and 1059290 and Program Grant 1113133), the Australian Cancer Research Foundation, the Leukemia and Lymphoma Society (U.S.) (SCOR grant 7001-03), the Victorian State Government Operational Infrastructure Support, the Australian Government NHMRC IRIISS, and we acknowledge the support of the Walter and Eliza Hall Institute through the Catalyst Fund.